New prospects for the treatment of germ-cell tumours

Bibliography

• EINHORN LH: Testicular cancer as a model for a curable neoplasm: the Richard and Hinda Rosenthal Founda-tion Award Lecture. Cancer Res. (1981) :3275–3280.
   PubMed Web of Science ®Google Scholar
• BOSL GJ, MOTZER RJ: Testicular cancer. New Engl. J. Med. (1997) 337:242–253.
   PubMed Web of Science ®Google Scholar
• ••The modern state of the art review.
   Google Scholar
• ULBRIGHT TM: Germ cell neoplasms of the testis. Am. J. Pathol. (1993) 17:1075–1091.
   Web of Science ®Google Scholar
• DROZ JP, KRAMAR A, REY A: Prognostic factors in meta-static disease. Semin. Oncol (1992) 19:181–189.
   PubMed Web of Science ®Google Scholar
• INTERNATIONAL GERM CELL COLLABORATIVE GROUP MEMBERS: International germ cell consensus classifi-cation: a prognostic factor-based staging system for metastatic germ cell cancers. J. Clin. Oncol. (1997) 2:594–603.
   Google Scholar
• ••The modern prognostic classification.
   Google Scholar
• WILLIAMS SD, BIRCH R, EINHORN LH et al: Treatment of disseminated germ-cell tumors with cisplatin, bleomy-cin and either vinblastine or etoposide. New Eng. J. Med. (1987) 316:1435–1440.
   PubMed Web of Science ®Google Scholar
• ••The cornerstone study.
   Google Scholar
• EINHORN LH, WILLIAMS SD, LOEHRER PJ et al.: Evalua-tion of optimal duration of chemotherapy in favourable-prognosis disseminated germ-cell tumors: a Southeastern Cancer Study Group protocol. J. Clin. Oncol. (1989) 7:387–391.
   PubMed Web of Science ®Google Scholar
• SAXMAN S, FINCH D, GONIN R, EINHORN LH: Long-term follow-up of a Phase III study of three versus four cy-cles of bleomycin, etoposide, and cisplatin in favourable-prognosis germ-cell tumors: the Indiana University experience. J. Gun. Oncol (1998) 16:702–706.
   Web of Science ®Google Scholar
• DE WIT R, STOTER G, KAYE SB et al.: Importance of bleo- mycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomised study of the European Organisation for Reseach and Treatment of Cancer Genitourinary Tract Cancer Co-operative Group. J. Gun. Oncol. (1997) 5:1837–1843.
   Google Scholar
• LOEHRER PJ, JOHNSON DH, ELSON P, EINHORN LH, TRUMP DL: Importance of bleomycin in favourable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J. Clin. Oncol. (1995) 13:470–476.
   PubMed Web of Science ®Google Scholar
• TONER GC, PANICEK DM, HEELAN RT et al: Adjunctive surgery after chemotherapy for non-seminomatous germ cell tumors: recommendations for patient selec-tion. J. Gun. Oncol. (1990) 8:1683–1694.
   Web of Science ®Google Scholar
• FOX EP, WEATHERS TD, WILLIAMS SD et al.: Outcome analysis for patients with persistent non-teratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J. Clin. Oncol. (1993) 11:1294–1299.
   PubMed Web of Science ®Google Scholar
• STEYERBERG EW, KEIZER HJ, SLEIJFER DT: Postchemo- therapy surgery in nonseminoma. J. Clin. Oncol. (1997) 9:3165–3168.
   Google Scholar
• DROZ JP, VAN OOSTEROM AT: Treatment options in clinical Stage I non-seminomatous germ cell tumours of the testis: a wager on the future? A review. Eur. J. Cancer (1993) 29A:1038–1044.
   PubMed Web of Science ®Google Scholar
• DROZ JP, HORWICH A: Extragonadal germ cell tumors. In: Comprehensive Textbook of Genitourinary Oncology. Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS (Eds.), Williams & Wilkins, Baltimore, USA (1996):1070–1074.
   Google Scholar
• CULINE S, KRAMAR A, BIRON P, DROZ JP: Chemotherapy in adult germ cell tumors. Crit. Rev. Oncol. Hematol. (1996) 22:229–263.
   PubMed Web of Science ®Google Scholar
• FIZAZI K, CULINE S, DROZ JP et al: Primary mediastinal non-seminomatous germ cell tumors: results of mod-ern therapy including cisplatin-based chemotherapy. Clin. Oncol (1998) 16:725–732.
   Web of Science ®Google Scholar
• EINHORN LH, WILLIAMS SD, TRONER M, BIRCH R, GRECOFA: The role of maintenance therapy in disseminated testicular cancer. New Eng. J. Med. (1980:727–731.
   PubMed Web of Science ®Google Scholar
• MCCAFFREY JA, MAZUMDAR M, BAJORIN DF et al: Ifosfa-mide and cisplatin containing chemotherapy as first-line salvage in germ cell tumors: response and sur-vival. J. Clin. Oncol (1997) 15:2559–2563.
   PubMed Web of Science ®Google Scholar
• DROZ JP, KRAMAR A, NICHOLS CR et al.: Second-line che-motherapy with ifosfamide, cisplatin and either eto-poside or vinblastine in reccurent germ cell cancer: assignement of prognostic groups. Proc. Am. Soc. Clin. Oncol. (1993) 12:229.
   Google Scholar
• SAMUELS ML, JOHNSON DE, HOLOYE PY: Continuous intravenous bleomycin (NSC-125066) therapy with vinblastine (NSC-49842) in Stage III testicular neopla-sia. Cancer Chemother. Rep. (1975) 59:563–570.
   PubMedGoogle Scholar
• BUCKNER CD, CLIFT RA, FEFER A et al.: High-dose cyclo-phosphamide (NSC-26271) for the treatment of meta-static testicular neoplasm. Cancer Chemother. Rep. (1974) 58:709–714.
   PubMedGoogle Scholar
• HIGBY DJ, WALLACE HJ, ALBERT D, HOLLAND JF: Diam-minodichloroplatinum in the chemotherapy of tes-ticular tumors. J. Urol. (1974) :100–104.
   PubMed Web of Science ®Google Scholar
• •The demonstration of cisplatin activity.
   Google Scholar
• WITTES RE, YAGODA A, SILVAY 0 et al.: Chemotherapy of germ cell tumors of the testis. Induction of remis-sions with vinblastine, actinomycin D and bleomycin. Cancer (1976) 37:637–645.
   Google Scholar
• EINHORN LH, DONOHUE JP: Cis-diammine- dichloro-platinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann. Intern. Med. (1977) 87:293–298.
   PubMed Web of Science ®Google Scholar
• EINHORN LH, WILLIAMS SD: Chemotherapy of dissemi-nated testicular cancer. A random prospective study. Cancer (1980) 46:1339–1344.
   Google Scholar
• SAMSON MK, RIVKIN SE, JONES SE et al.: Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. A Southern Oncology Group Study. Cancer (1984) 53:1029–1035.
   Google Scholar
• •The demonstration that suboptimal dose-intensity (18.5 mg/m2/week) is less active than standard cisplatin dosage (30 mg/m2/week).
   Google Scholar
• BAJORIN DF, BOSL GJ: Bleomycin in germ cell tumor therapy: not all regimens are created equal. J. Clin. On-col. (1997) 15:1717–1719.
   PubMed Web of Science ®Google Scholar
• CVITKOVIC E: Bleomycin in nonseminomatous germ-cell tumors: cure rate versus morbidity. J. Ciin. Oncol (1998) 16:799–800.
   PubMed Web of Science ®Google Scholar
• OZOLS RF, IHDE DC, LINEHAN WM et al.: A randomised trial of standard chemotherapy vs. a high dose chemo-therapy regimen in the treatment of poor prognosis metastatic non-seminomatous germ-cell tumors. J. Clin. Oncol. (1988) 6:1031–1040.
   Google Scholar
• NICHOLS CR, WILLIAMS S, LOEHRER PJ et al.: Random-ised study of cisplatin dose-intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J. Clin. Oncol (1991) 9:1163–1172.
   PubMed Web of Science ®Google Scholar
• ••This study demonstrates that higher cisplatin dose-intensityincreases toxicity but fails to increase efficacy.
   Google Scholar
• NICHOLS CR, LOEHRER PJ, EINHORN LH et al.: Phase III study of cisplatin, etoposide and bleomycin or etopo-side, ifosfamide and cisplatin in advanced stage germ-cell tumors: an intergroup trial (abstract). Proc. Am. Soc. Clin. Oncol (1995) 14:239.
   Google Scholar
• LOEHRER PJ, LAUER R, ROTH BJ et al: Salvage therapy in recurrent germ-cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann. Intern. Med. (1988) 109:540–546.
   PubMed Web of Science ®Google Scholar
• EINHORN LH: Treatment of testicular cancer: a new and improved model. J Clin. Oncol. (1990) 8:1777–1781.
   PubMed Web of Science ®Google Scholar
• ••Classical state-of-the-art review. EINHORN LH: Treatment of testicular cancer: a new and improved model. J Clin. Oncol. (1990) 8:1777-1781. Classical state-of-the-art review. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(7)
   Google Scholar
• DE WIT R, SLEIJFER DT, KAYE SB et al: Four cycles of BEP versus an alterning regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma: a randomised study of the EORTC Genetou-rinary Tract Cancer Cooperative Group. Br. J. Cancer (1995) 71:1311–1314.
   PubMed Web of Science ®Google Scholar
• KAYE SB, MEAD GM, FOSSA S et al.: Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis meta-static nonseminomatous germ cell tumour: a random-ised Medical Research Council/European Organisation for Research and Treatment of Cancer Study. J. Clin. Oncol. (1998) 2:692–701.
   Google Scholar
• DROZ JP, PICO JL, BIRON P et al: No evidence of a benefit of early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor-risk non-seminomatous germ cell tumours: pre-liminary results of a randomised trial. Proc. Am. Soc. Oncol. (1992) 11:197.
   Google Scholar
• TRUMP DL, ELSON P, BRODOVSKY H, VOGL SE: Carbo-platin in advanced, refractory germ cell neoplasms: a Phase II Eastern Cooperative Oncology Group Oncol-ogy Study. Cancer Treat. Rep. (1987) 71:989–990.
   PubMedGoogle Scholar
• MOTZER RJ, BOSL GJ, TAUER K, GOLBEY R: Phase II trial of carboplatin in patients with advanced germ cell tu-mours refractory to cisplatin. Cancer Treat. Rep. (1987) 71:197–198.
   PubMedGoogle Scholar
• KATTAN J, MAHJOUBI M, DROZ JP et al.: High failure rateof carboplatin-etoposide combination in good risk non-seminomatous germ cell tumours. Eur. J. Cancer (1993) 29A:1504–1509.
   PubMed Web of Science ®Google Scholar
• BAJORIN D, SAROSDY MF, PFISTER DG eta].: Random-ised trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multi-institutional study. J. Clin. Oncol. (1993) 4:598–606.
   Google Scholar
• HORWICH A, SLEIJFER DT, FOSSA SD et al.: Randomisedtrial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a multi-institutional Medical Research Coun-cil/European Organisation for Research and Treat-ment of Cancer Trial. J. Clin. Oncol. (1997) 5:1844–1852.
   Google Scholar
• HORWICH A, DEARNALEY DP, NICHOLLS J et al.: Effec-tiveness of carboplatin, etoposide, and bleomycin combination chemotherapy in good-prognosis meta-static testicular nonseminomatous germ cell tumours. Clin. Oncol (1991) 1:62–69.
   Google Scholar
• SOULIE P, RAYMOND E, MISSET JL, CVITKOVIC E: Oxali-platin: update on an active and safe DACH-platinum complex. In: Platinum and Other Metal Co-ordination Compounds in Cancer Chemotherapy. Pinedo HM, Schorn-agel JH (Eds.), Plenum Press, New York (1996):165–174.
   Google Scholar
• SCHULTZ SM, LOEHRER P, WILLIAMS S, EINHORN L: APhase II trial of epirubicin (EN) in the salvage therapy of germ cell tumors. Proc. Am. Soc. Clin. Oncol. (1987) 6:99.
   Google Scholar
• LECESNE A, DROZ JP, AZAB M et al.: Phase II trial withsingle agent epirubicin (EN) as salvage chemotherapy (CT) in refractory germ cell tumors (RGCT). Proc. Am. Soc. Clin. Oncol (1990) 9:145.
   Google Scholar
• MONFARDINI S, BAJETTA E, MUSUMECI R, BONADONNAG: Clinical use of adryamicin in advanced testicular cancer. J. Urol. (1972) 108:293–296.
   PubMed Web of Science ®Google Scholar
• SMITH DB, RUSTIN GJS, HITCHINS RN, BAGSHAWE KD, HOSKINS P: Single agent activity of methotrexane in advanced non-seminomatous testicular germ cell tu-mours. Eur. J. Cancer Clin. Oncol (1988) 11:1779–1781.
   Google Scholar
• HOSKINS P, COPPIN CML, MURRAY N: Mitomycin is ac-tive against refractory germ-cell tumors. Am. J. Clin. Oncol. (1990) 13:35–38.
   PubMed Web of Science ®Google Scholar
• CASPER J, SCHMOLL HJ, SCHNAIDT U, FONATSCH C: Cell-lines of human germinal cancer. Int. J. Androl (1987) 10:105–113.
   PubMed Web of Science ®Google Scholar
• BRONSON L, ANDREWS PW, SOLTER D et al: Cell-line de-rived from a metastasis of a human testicular germ cell tumour. Cancer Res. (1980) 40:2500–2508.
   PubMed Web of Science ®Google Scholar
• CHOU TC, MOTZER RJ, TONG Y, BOSL GJ: Computerized quantitation of synergism and antagonism of taxol, to-potecan, and cisplatin against human teratocarci-noma cell growth: a rational approach to clinical protocol design. J. Nati Cancer Inst. (1994) 86:1517–1524.
   PubMed Web of Science ®Google Scholar
• ••A very interesting in vitro model to test chemotherapy activ-ity in germ cell tumours.
   Google Scholar
• SKEHAN P, STORENG R, MONKS A et al.: New colorimet-ric cytotoxicity assay for anticancer drug screening. J. Natl. Cancer Inst. (1990) 82:1107–1112.
   PubMed Web of Science ®Google Scholar
• DUNN TA, SCHMOLL HJ, GRUNWALD V, BOKEMEYER C,CASPER J: Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell-lines. Invest. New Drugs (1997) 15:109–114.
   PubMed Web of Science ®Google Scholar
• HARSTRICK A, BOKEMEYER C, SCHARNOFKSE M et al Preclinical activity of a new platinum analog, lo-baplatin, in cisplatin-sensitive and resistant human testicular, ovarian, and gastric carcinoma cell-lines. Cancer Chemother. Pharmacol. (1993)43–47.
   PubMed Web of Science ®Google Scholar
• HARSTRICK A, CASPER J, KOHNE-WOMPNER H et al.: Comparative activity of four anthracyclines against heterotransplanted germ cell tumor lines. Invest. New Drugs (1990) 8:519–S24.
   Web of Science ®Google Scholar
• DUNN TA, GRUNWALD V, BOKEMEYER C, CASPER J: Pre-clinical activity of taxol in non-seminomatous germ cell tumor cell-lines and nude mouse xenografts. In-vest. New Drugs (1997) 15:91–98.
   PubMed Web of Science ®Google Scholar
• HARSTRICK A, CASPER J, GUBA R et al.: Comparison of the antitumour activity of cisplatin, carboplatin, and iproplatin against established human testicular cancer cell-lines in vivo and in vitro. Cancer (1989) 63:1079–1083.
   PubMed Web of Science ®Google Scholar
• HARSTRICK A, SCHMOLL HJ, CASPER J, WILKE H, PALI-WODA H: Activity of cytostatic drugs in two hetero-transplanted human testicular cancer cell-lines with different sensitivity to standard agents. Eur. J. Cancer (1990) 26:898–901.
   PubMed Web of Science ®Google Scholar
• JOHNSTON PG, KLEINER D, COWAN KH: Fazarabine: areport of response in a patient with multiply relapsed embryonal cell carcinoma. Am. J. Clin. Oncol. (1993) 16:34–37.
   PubMed Web of Science ®Google Scholar
• STENDER MJ, LOEHRER PJ, WILLIAMS SD, FINCH DE, EIN-HORN LH: A Phase II trial of gemcitabine in relapsed re-fractory germ cell tumor. Proc. Am. Soc. Clin. Oncol. (1998) 17:321a.
   Google Scholar
• PUC HS, BAJORIN DF, AMSTERDAM A, MOTZER RJ: PhaseII trial of topotecan in patients with cisplatin-refractory germ cell tumors. Invest. New Drugs (1995) 13:163–165.
   PubMed Web of Science ®Google Scholar
• MOTZER RJ, DMITROVSKY E, MILLER WH et al: Suraminfor germ cell tumors. Cancer (1993) 72:3313–3317.
   PubMed Web of Science ®Google Scholar
• GOLD EJ, BOSL GJ, ITRI LM: Phase II trial of 13-cis-retinoic acid in patients with advanced nonseminoma-tous germ cell tumors. Cancer Treat Rep. (1984) 68:1287–1288.
   PubMedGoogle Scholar
• MOASSER MM, MOTZER RJ, KHOO K et al.: All-trans reti-noic acid for treating germ cell tumors. Cancer (1995):680–686.
   PubMed Web of Science ®Google Scholar
• MOTZER RJ, BAJORIN DF, BOSL GJ et al.: Paclitaxel (T)containing first-line salvage therapy selected by risk for patients (pts) with germ cell tumors (GCT). Proc. Am. Soc. Clin. Oncol. (1997) 16:322a
   Google Scholar
• RODENHUIS S, VLASVELD LT, DUBRELMAN R et al: Feas-ability study of high-dose carboplatin and etoposide in the salvage treatment of testicular cancer. Ann. Oncol. (1992) 3:463–467.
   PubMed Web of Science ®Google Scholar
• LOTZ JP, ANDRE T, DONSIMONI R et al.: High-dose che-motherapy with ifosfamide, carboplatin, and etopo-side combined with autologous bone marrow transplantation for the treatment of poor prognosis germ-cell tumors and metastatic trophoblastic disease in adults. Cancer (1995) 75:874–885.
   PubMed Web of Science ®Google Scholar
• BOKEMEYER C, SCHMOLL HJ, HARSTRICK A et al: APhase I/II study of stepwise dose-escalated regimen of cisplatin, etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumors. Eur. J. Cancer (1993) 29A:2225–2231.
   PubMed Web of Science ®Google Scholar
• BOKEMEYER C, SCHMOLL HJ, KUCZYK MA, BEYER J, SIEGERT W: Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer. J. Nati Cancer Inst. (1995) 87:58–59.
   PubMed Web of Science ®Google Scholar
• BOKEMEYER C, HARSTRICK A, RUTHER U et al.: Sequen-tial treatment with high-dose VIP-chemotherapy plus peripheral blood stem cell support in advanced germ cell cancer. Proc. Am. Soc. Clin. Oncol. (1995) 14:230.
   Google Scholar
• DROZ JP, CULINE S, BIRON P, KRAMAR A: High dose che-motherapy in germ-cell tumors. Ann. Oncol. (1996) 7:997–1003.
   PubMed Web of Science ®Google Scholar
• CULINE S, DROZ, JP, DELVA R et al.: Rapidly recycled in-tensive alternating chemotherapy in heavily pre-treated progressive non-seminomatous germ-cell tumours. A feasibility study Urol Oncol (1995) 1:109–114.
   PubMedGoogle Scholar
• MOTZER RJ, BAJORIN DF, SCHWARTZ LH et al.: Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumours. J. Clin. On-col. (1994) 12:2277–2283.
   PubMed Web of Science ®Google Scholar
• BOKEMEYER C, BEYER J, METZNER B et al.: Phase II study of paclitaxel in patients with relapsed or cisplatin re-fractory testicular cancer. Ann. Oncol. (1996) 7:31–34.
   PubMed Web of Science ®Google Scholar
• JACOBS EM: Combination chemotherapy of metastatic testicular germinal cell tumors and soft part sarcomas. Cancer (1970) 25:324–332.
   PubMedGoogle Scholar
• STEINFELD JL, SOLOMON J, MARSH AA, HAZEN JG, BATE-MAN JR: Chemical therapy of patients with advanced metastatic germinal tumors. J. Urol. (1966) 96:933–940.
   PubMed Web of Science ®Google Scholar
• REAM NW, PERLIA CP, WOLTER J, TAYLOR SG: Mithramy-cin therapy in disseminated germinal testicular can-cer. JAMA (1968) 204:96–102.
   Web of Science ®Google Scholar
• MERRIN CE, MURPHY GP: Metastatic testicular carci-noma. Single-agent chemotherapy (actinomycin D) in treatment. NY Stat. J Med. (1974) 74:654–657.
   PubMedGoogle Scholar
• MACKENZIE AR: Chemotherapy of metastatic testis can-cer. Results in 154 patients. Cancer (1966) 19:1369–1376.
   Google Scholar
• SAMUELS ML, HOWE CD: Vinblastine in the manage-ment of testicular cancer. Cancer (1970) 25:1009–1017.
   PubMed Web of Science ®Google Scholar
• LI MC, WHITMORE WF, GOLBEY R, GRABSTALD H: Ef-fects of combined drug therapy on metastatic cancer of the testis. JAMA (1960) 174:1291–1299.
   PubMed Web of Science ®Google Scholar
• •Historic: the first active chemotherapy regimen in germ cell tumors.
   Google Scholar
• ANSFIELD FJ, KORBITZ BC, DAVIS HL, RAMIREZ G: Triple drug therapy in testicular tumors. Cancer (1969) 24:442–446.
   PubMed Web of Science ®Google Scholar
• SOLOMON J, STEINFELD JL, BATEMAN JR: Chemother-apy of germinal tumors. Cancer (1967) 20:747–750.
   PubMed Web of Science ®Google Scholar
• MENDELSON D, SERPICK AA: Combination chemother-apy of testicular tumors. J. Urol. (1970) 103:619–623.
   PubMed Web of Science ®Google Scholar
• WILLIAMS SD, EINHORN LH, GRECO FA, OLDHAM R, FLETCHER R: VP-16-213 salvage therapy for refractory germinal neoplasms. Cancer (1980) 46:2154–2158.
   PubMed Web of Science ®Google Scholar
• BREMER K, NIEDERLE N, KRISCHKE W et al.: Etoposide and etoposide-ifosfamide therapy for refractory tes-ticulars tumors. Cancer Treat. Rev. (1982) 9:79–84.
   PubMed Web of Science ®Google Scholar
• HAINSWORTH JD, WILLIAMS SD, EINHORN LH, BIRCH R, GRECO FA: Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: results of a South-eastern Cancer Study Group Trial. J. Clin. Oncol. (1985) 3:666–671.
   PubMed Web of Science ®Google Scholar
• SCHMOLL HJ: The role of ifosfamide in testicular can-cer. Contr. Oncol. (1987) 26:234-255. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1998) 7(7)
   Google Scholar
• HARTLAPP JH, WEISSBACH L, HORSTMANN-DUBRAL B:Ifosfamide monotherapy in testicular cancer. Contr. Oncol. (1987) 26:256–261.
   Google Scholar
• SCHEULEN ME, NIEDERLE N, HOFFKEN K et al.: Chemo-therapy of disseminated non-seminomatous testicular cancer and metastatic seminoma with ifosfa-mide/mesna. Contr. Oncol. (1987) 26:278–286.
   Google Scholar
• WHEELER BM, LOEHRER PJ, WILLIAMS SD, EINHORN LH:Ifosfamide in refractory male germ cell tumors. J. Clin. Oncol. (1986) 4:28–34.
   PubMed Web of Science ®Google Scholar
• O'REILLY SM, RUSTIN GJS, SMITH DB, NEWLANDS ES: Sin-gle agent activity of carboplatin in patients with previ-ously untreated non-seminomatous germ cell tumours. Ann. Oncol. (1992) 3:163–164.
   PubMed Web of Science ®Google Scholar
• DRASGA RE, WILLIAMS SD, EINHORN LH, BIRCH R: PhaseII evaluation of iproplatin in refractory germ cell tu-mors: a Southeastern Cancer Study Group trial. Cancer Treat. Rep. (1987) 71:863–864.
   PubMedGoogle Scholar
• CLAVEL M, MONFARDINI S, SIEGENTHALER P, PINEDOHM, RENARD J: Phase II trial of CHIP in previously treated disseminated testicular cancer. Proc. Am. Soc. Oncol. (1986) 5:108.
   Google Scholar
• NITSCHKE R, PRATT CB, KRISCHER J et al: Evaluation ofCHIP (iproplatin) in recurrent pediatric malignant solid tumors. A Phase II study (Pediatric Oncology Group). Invest. New Drugs (1992) 10:93–96.
   PubMed Web of Science ®Google Scholar
• CHUN H, BOSL GJ, GOLBEY RB: Phase II trial of 1,2 dia-minocyclohexane-(4-carboxyphthalato) platinum(I) in patients with refractory germ cell tumors. Cancer Treat. Rep. (1985) 69:459–460.
   PubMedGoogle Scholar
• BOKEMEYER C, KOHRMANN 0, TISCHLER J et al. A ran- domised trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with good-risk metastatic non-seminomatous germ cell tumours. Ann. Oncol. (1996):1015–1021.
   Google Scholar
• EINHORN LH, DONOHUE JP: Improved chemotherapyin disseminated testicular cancer. J. Urol. (1977)65–69.
   PubMed Web of Science ®Google Scholar
• HIGBY DJ, WALLACE HJ, HENDERSON ES, WEISS R: Adriamycin-cyclophosphamide and adriamycin-cis-dichloro-diammineplatinum(I) combination chemo-therapy in patients with advanced cancer. Cancer Treat. Rep. (1977) 61:869–873.
   PubMedGoogle Scholar
• VOGL SE, OHNUMA T, PERLOFF M, HOLLAND JF: Combi-nation chemotherapy with adryamicin and cis-diamminedichloroplatinum in patients with neoplas-tic diseases. Cancer (1976) 38:21–26.
   PubMed Web of Science ®Google Scholar
• LEDERMAN GS, GARNICK MB, CANELLOS GP, RICHIE JP: Chemotherapy of refractory germ cell cancer with eto-poside. j Clin. Oncol (1983) 11:706–709.
   Google Scholar
• STOTER G, AKDAS A, FOSSA SD et al: High-dose epirubi-cin in chemotherapy refractory non-seminomatous germ cell cancer: a Phase II study. Ann. Oncol (1992) 3:577–578.
   PubMed Web of Science ®Google Scholar
• HARSTRICK A, SCHMOLL HJ, WILKE H et al.: High dose epirubicin in refractory or relapsed non-seminomatous testicular cancer: a Phase II study. Ann. Oncol (1990) 1:375–376.
   PubMed Web of Science ®Google Scholar
• REYNOLDS TF, VUGRIN D, CVITKOVIC E, GRALLA RJ, GOLBEY RB: Phase II trial of vindesine in patients with germ-cell tumors. Cancer Treat. Rep. (1979) 63:1399–1401.
   PubMedGoogle Scholar
• BOKEMEYER C, DROZ JP, HANAUSKE A et al.: Treatment of relapsed nonseminomatous germ cell tumours with vinorelbine: a trial of the Phase I/II study group of the Association for Medical Oncology of the German Can-cer Society. Onkologie (1993) 16:29–31.
   Web of Science ®Google Scholar
• CHU H, BOSL GJ: Phase II trial of mitoguazone in pa-tients with refractory germ cell tumors. Cancer Treat. Rep. (1985) 69:461–462.
   PubMedGoogle Scholar
• WILLIAMS SD, BIRCH R, GAMS R, IRWIN L: Phase II trial of mitoxantrone in refractory germ cell tumours: a trial of the Southeastern Cancer Study Group. Cancer Treat. Rep. (1985) 69:1455–1456.
   PubMedGoogle Scholar
• DE JAGER R, CAPPELAERE P, ARMAND JP et al.: An EORTC Phase II study of mitoxantrone in solid tumours and lymphomas. Eur. J. Cancer Clin. Oncol. (1984) 20:1369–1375.
   PubMedGoogle Scholar
• WILLIAMS SD, DUNCAN P, EINHORN LH: Phase II study of AMSA in refractory testicular cancer. Cancer Treat. Rep. (1983) 67:309–310.
   PubMedGoogle Scholar
• DE JAGER R, SIEGENTHALER P, DOMBERNOWSKY P: Phase II study of 4 '-(9-acridinylamino)-methan sulfon-m-amside (m-AMSA). Proc. Am. Assoc. Cancer Res. (1981) 22:367.
   Google Scholar
• ATKINSON C, HORWICH A, PECKHAM MJ: Methotrexate for relapse of metastatic non-seminomatous germ-cell tumours. Med. Oncol. tumor Pharmacother. (1987) 1:33–37.
   Google Scholar
• CHRISTOU A, ROTH B, FOX S et al.: Phase II trial of pacli-taxel in refractory germ cell neoplasms. Proc. Am. Soc. Clin. Oncol (1996) 15:249.
   Google Scholar